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Abstract: 4-Amino-7-(5′-deoxy-β-D-xylofuranosyl)-5-iodo-pyrrolo[2,3-d]pyrimidine 1, an 
unusual naturally occurring marine nucleoside isolated from an ascidan, Diplosoma sp., 
was synthesized from D-xylose in seven steps with 28% overall yield on 10 g scale. The 
key step was Vorbrüggen glycosylation of 5-iodo-pyrrolo[2,3-d]pyrimidine with 5-deoxy-1, 
2-O-diacetyl-3-O-benzoyl-D-xylofuranose. Its absolute configuration was confirmed. 
Keywords: Vorbrüggen glycosylation; total synthesis; pyrrolo[2,3-d]pyrimidine;  
marine nucleoside 
 
1. Introduction 
Naturally occurring deazapurine nucleosides, such as tubercidin [1], toyocamycin [2], sangivamycin [3], 
cadeguomycin [4] and recently isolated marine nucleoside 5-iodo-5′-deoxytubercidin, mycalesine A 
and  B [5], showed significant biological activities. Structurally related pyrrolo[2,3-d]pyrimidine 
nucleosides have triggered the continued interest of medicinal chemists in the past decades [6–8]. 
Although many uncommon nucleosides have been isolated from terrestrial and marine   
organisms [5,9,10], nucleosides containing D-xylofuranose are rare in nature [11]. In 2008,   
4-amino-7-(5′-deoxy-β-D-xylofuranosyl)-5-iodo-pyrrolo[2,3-d]pyrimidine  1 was first isolated by 
Japanese scientists from an ascidan, Diplosoma sp. It was found that nucleoside 1 causes complete 
inhibition of cell division in fertilized sea urchin eggs at 1 µg/mL concentration [12]. This compound 
is a potential lead for development of new insecticides. As part of our continuing effort for synthesis of 
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bioactive natural 7-deazapurine nucleosides, we report the first total synthesis and structure 
confirmation of 1. 
2. Results and Discussion 
In nucleoside chemistry, Vorbrüggen glycosylation (Silyl-Hilbert-Johnson reaction) is one of the 
most efficient approaches for nucleoside synthesis. This reaction has been widely applied in academic 
and industrial research [13–15]. According to the proposed mechanism of Vorbrüggen glycosylation, 
silylated nucleobase attacks the intermediate oxonium to give desired nucleoside. Different from 
purine and pyrimidine nucleobases, such as adenine and thymine, pyrrolo[2,3-d]pyrimidines  
(7-deazapurine) were seldom used as donors in Vorbrüggen glycosylation. The reason might be 
possibly ascribed to the nonreactive nature of N-7 in pyrrolo[2,3-d]pyrimidines [16,17]. 
In order to circumvent this problem, nucleobase-anion glycosylation protocol was developed for the 
synthesis of 7-deazapurine nucleosides and their analogues by Robins [18,19] and Seela [20–22]. In 
this approach, labile α-D-furanosyl chloride intermediates, such as 2, must be prepared via a lengthy 
synthetic route with poor yield [23,24] (Figure 1). This drawback limits its application.  
Figure 1. Chemical structure of pyrrolo[2,3-d]pyrimidine nucleoside 1 and its 
retrosynthetic analysis. 
 
From a synthetic point of view, Vorbrüggen glycosylation is one of the ideal choices for synthesis 
of pyrrolo[2,3-d]pyrimidine nucleosides because of commercial availability of carbohydrate acceptors. 
Recently, it was found that pyrrolo[2,3-d]pyrimidine nucleobases with electro-withdrawing groups 
(such as Cl, Br, I, etc.) at 5-position can be successfully used as donors in Vorbrüggen glycosylation 
for the preparation of pyrrolo[2,3-d]pyrimidine nucleosides with good yields [25–28]. However, its 
application in synthesis of xylofuranose pyrrolo[2,3-d]pyrimidine nucleosides has not been reported. It 
is important to further prove this protocol’s generality and reproducibility. We herein report a practical 
and efficient synthesis of 1 from D-xylose with application of Vorbrüggen glycosylation as the key 
step (Scheme 1). Mar. Drugs 2012, 10 883 
 
Scheme 1. Total synthesis of pyrrolo[2,3-d]pyrimidine nucleoside 1. Reagents and 
conditions: (a) (a1) Conc. H2SO4, acetone, 0 °C, 3 h; (a2) 5% Na2CO3 aq., 30 min, 87%;  
(b) TsCl (1.1 eq.), THF, Et3N, 0 °C, overnight, 92%; (c) LiAlH4 (0.5 eq.), THF, reflux, 6 h, 
95%; (d) BzCl (1.1 eq), CH2Cl2, Et3N, 2 h, 98%; (e) Conc. H2SO4, Ac2O, 26 h, 78%;  
(f) POCl3 (excess), reflux, 3 h, 98%; (g) NIS (1.01 eq.), DMF, 0 °C, 2 h, 98%; (h) 4 (1 eq.), 
BSA (1.2 eq.), TMSOTf (1 eq.), CH3CN, rt-80 °C, 12 h 56%; (i) Sat. NH3 in MeOH 
(excess), 130 °C, 12 h, 82%. 
 
5-Deoxy-D-xylose glycosylation acceptor 3 was synthesized starting with D-xylose 5. Crystalline 
1,2-O-isopropylidene-α-D-xylofuranose  6 was prepared in 87% yield by sulfuric acid-catalyzed 
acetalation of D-xylose, followed by partial hydrolysis with aqueous sodium carbonate added directly 
to the crude acetalation mixture in one pot [29]. Then 5-OH was selectively tosylated with   
p-toluenesulfonyl chloride and triethylamine in THF to afford monotosylate 7 in 92% yield. After 
refluxing with 2 equiv. of LiAlH4 in anhydrous THF, the tosylate was reduced to a methyl group in 
excellent 95% yield to afford 8 [30]. Subsequent benzoylation of 3-OH gave compound 9 in almost 
quantitative yield. Finally, the acetonide 9 was transformed to D-xylose diacetate glycosylation 
acceptor 3 as a mixed isomers (α:β = 2:3) on 50 g scale [31]. Mar. Drugs 2012, 10 884 
 
For preparation of nucleobase 4, chlorination of pyrrolo[2,3-d]pyrimidin-4-ol 11 with phosphoryl 
chloride gave 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 12 in 93% yield [32,33]. The reaction of 12 with 
1.05 equiv. of NIS in DMF at room temperature afforded the iodinated base 4 in 95% yield on 100 g 
scale [25]. 
Next, we intended to synthesize the target molecule 1 using Vorbrüggen glycosylation. After 
extensive optimization of various Lewis acids, solvents, reaction temperature, it was found that the 
best condition were the useof 1.2 equiv. of bis(trimethylsilyl)acetamide (BSA) as silylating reagent, 
2 equiv. oftrimethylsilyl triflate (TMSOTf) as Lewis acid, freshly distilled acetonitrile as solvent, and 
heating at 80 °C for 12 h. Then 1 equiv. 5-iodo-7H-pyrrolo[2,3-d]pyrimidine 4 was first treated with 
1.2 equiv. of BSA, followed by 1.2 equiv. of 5′-deoxy-1,2,3-tri-O-acetyl-β-D-xylofuranose  3 and 
2 equiv. of TMSOTf at room temperature. The resulting mixture was heated to 80 °C for 12 h. After 
workup, column chromatography afforded 4-chloro-7-(5′-deoxy-β-D-xylofuranosyl)-5-iodo-pyrrolo 
[2,3-d]pyrimidine 10 in 56% yield as pure β anomer on 20 g scale. The glycosylation yield was lower 
than that of the corresponding 5′-deoxy-1,2,3-tri-O-acetyl-D-ribofuranose acceptor, which typically 
gave more than 80% yield [25]. It may be due to the steric hindrance of 3′-β substitute. At last, 10 was 
suspended in a saturated solution of ammonia in methanol, and the resulting solution was heated at 
130 °C in an autoclave for 12 h to remove the protecting ester groups and substitute the 4-Cl by 4-NH2 
on the base. The target nucleoside 1 [12] was obtained in 82% yield on 10 g scale (Scheme 1), which is 
sufficient for further biological studies and structure modification. 
Because both D and L carbohydrate are present in marine natural products, Ueda and coworkers 
synthesized dibenzoates of 1 and 1-methyl-O-5-deoxy-β-L-xylofuranoside and compared their CD 
spectra to determine the absolute configuration of 1 [12]. According to their opposite cotton effect 
curves, the absolute configuration of 1 was indirectly determined to be D. In order to further confirm 
its precise configuration, the CD spectrum of synthesized 1 was determined and found identical to 
reported data [λext 242 nm (∆ε −1.9) and λext 210 nm (∆ε −2.6)]. Furthermore, because the starting 
material is D-xylose, the absolute configuration of nucleoside 1 is undoubtedly D. All other spectral 
data are in agreement with that of the reported natural nucleoside 1 [12]. 
3. Experimental Section 
3.1. General 
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine was synthesized in our lab on 500 g scale. BSA and 
TMSOTf were purchased from Sigma Aldrich. MeCN was dried over CaH2 and distilled prior to use. 
Thin layer chromatography was performed using silica gel GF-254 plates (Qing-Dao Chemical 
Company, Qingdao, China) with detection by UV (254 nm), or charting with 10% sulfuric acid in 
ethanol. Column chromatography was performed on silica gel (200–300 mesh, purchased from   
Qing-Dao Chemical Company, Qingdao, China). NMR spectra were recorded on a Bruker AV400 
spectrometer and chemical shifts (δ) are reported in ppm. 
1H NMR and 
13C NMR spectra were 
calibrated with TMS as internal standard and coupling constants (J) are reported in Hz. The   
ESI-HRMS were obtained on a Bruker Dalton microTOFQ II spectrometer in positive ion mode. Mar. Drugs 2012, 10 885 
 
3.2. Synthesis of 1,2-O-Isopropylidene-α-D-xylofuranose 6 
D-Xylose (20.0 g, 134 mmoL) was suspended in acetone (500 mL) containing concentrated H2SO4 
(20.0 mL, 98%). The mixture was stirred for 30 min at room temperature. Then a solution of Na2CO3 
(26.0 g, 246 mmol) in water (224 mL) was added carefully with cooling to 0 °C. After addition, the 
mixture was stirred for a further 3 h. Then, solid Na2CO3 (14.0 g, 132 mmoL) was added in 3 portions 
over 30 min. The resulted Na2SO4 was filtered off and washed with acetone. The combined filtrates 
were evaporated to give crude 6, which was purified by a silica gel column (CHCl3:Me2CO = 18:1,  
Rf = 0.32) to afford crystallized 6 (22.2 g, 87%). mp 42–43 °C; 
1H NMR (400 MHz, CDCl3) δ: 5.97  
(d, J = 4.4 Hz, 1H), 4.51 (d, J = 4.4 Hz, 1H), 4.31 (d, J = 2.0 Hz, 1H), 4.27 (d, J = 4.4 Hz, 1H), 4.16  
(q, 1H), 4.09 (d, J = 4.8 Hz, 1H), 4.03 (d, J = 2.8 Hz, 1H), 2.04 (s, 1H), 1.47 (s, 3H), 1.31 (s, 3H);  
13C NMR (100 MHz, CDCl3) δ: 111.8, 104.8, 85.6, 78.8, 78.7, 61.0, 26.7, 26.2. 
3.3. Synthesis of 5-O-Tosylate-1,2-O-isopropylidene-α-D-xylofuranose 7 
A solution of TsCl (83.9 g, 440 mmoL) in THF (500 mL) was added slowly to 1,2-O-isopropy 
lidene-α-D-xylofuranose 6 (76.1 g, 400 mmol) in THF (400 mL) and Et3N (300 mL) at 0 °C. After 
addition, the solution was stirred at room temperature overnight. CH3OH (10 mL) was added to quench 
the reaction. After filtration, the resulting solution was evaporated to dryness. The residue was 
dissolved in EtOAc (500 mL) and washed with H2O (100 mL), sat. NaHCO3 (100 mL) and brine (100 mL), 
then dried with anhydrous Na2SO4. After filtration, the solution was evaporated under reduced pressure. 
The residue was purified over a silica gel column (EtOAc:Hexane = 1:1) to afford 7 (126.7 g, 92%). 
mp 134–135 °C; 
1H NMR (400 MHz, CDCl3) δ: 7.80 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 
5.88 (d, J = 4.8 Hz, 1H), 4.52 (d, J = 3.6 Hz, 1H), 4.34~4.31 (m, 3H), 4.13 (q, 1H), 2.46 (s, 3H), 2.27 
(d, J = 4.8 Hz, 1H), 1.59 (s, 1H), 1.47 (s, 3H), 1.30 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ: 145.3, 
132.4, 130.0, 128.0, 112.2, 104.9, 85.0, 76.7, 74.3, 66.0, 26.8, 26.2, 21.7; MS (ESI) m/z 345.2 [M + H]
+. 
3.4. Synthesis of 5-Deoxy-1,2-O-isopropylidene-α-D-xylofuranose 8 
LiAlH4 (3.8 g, 100 mmol) was added in portions to 5-O-tosylate-1,2-O-isopropylidene-α-D-xylo 
furanose 7 (68.9 g, 200 mmol) in anhydrous THF (800 mL). The resulting suspension was refluxed for 
6 h. EtOAc (50 mL) was added slowly to quench the reaction. Then H2O (100 mL) was added and the 
suspension was stirred for 2 h at room temperature. After filtration over Celite, the filtrate was 
evaporated to remove THF. EtOAc (500 mL) was added. The solution was washed with H2O (100 mL), 
sat. NaHCO3 (100 mL) and brine (100 mL), then dried with anhydrous Na2SO4. After filtration, the 
solution was evaporated under reduced pressure. The residue was purified over a silica gel column 
(EtOAc:Hexane = 1:2, Rf = 0.35) to afford 8 (33.0 g, 95%) as white solid. mp 81–83 °C; 
1H NMR 
(400 MHz, CDCl3) δ: 5.83 (d, J = 3.6 Hz, 1H), 4.47 (d, J = 3.6 Hz, 1H), 4.25 (t, 1H), 3.93 (s, 1H), 2.78 
(d, J = 4.0 Hz, 1H), 1.44 (s, 3H), 1.24 (d, J = 8.0 Hz, 6H); 
13C NMR (100 MHz, CDCl3) δ: 111.4, 
104.3, 85.5, 76.2, 76.1, 26.5, 26.1, 12.8; MS (ESI) m/z 175.3 [M + H]
+. Mar. Drugs 2012, 10 886 
 
3.5. Synthesis of 5-Deoxy-3-O-benzoyl-1,2-O-isopropylidene-α-D-xylofuranose 9 
Benzoyl chloride (8.71 g, 62 mmol) was added slowly to a solution of 5-deoxy-1,2-O-isopropy 
lidene-α-D-xylofuranose 8 (9 g, 51.7 mmol) in anhydrous pyridine (100 mL) at 0 °C. The resulting 
solution was stirred for 2 h at room temperature. Ethanol (0.5 mL) was added to quench the reaction. It 
was evaporated under reduced pressure to dryness. The residue was dissolved in DCM (300 mL) and 
washed with H2O (50 mL), sat. NaHCO3 (50 mL) and brine (50 mL), then dried with anhydrous 
Na2SO4. After filtration, the resulting solution was evaporated under reduced pressure. The residue 
was purified over a silica gel column (EtOAc:Hexane = 1:3, Rf = 0.3) to afford 9 (14.0 g, 98%) as 
white solid. 
1H NMR (400 MHz, CDCl3) δ: 8.02 (d, J = 7.6 Hz, 2H), 7.57 (t, 1H), 7.41 (t, 2H), 5.95  
(d, J = 3.6 Hz, 1H), 5.32 (d, J = 2.4 Hz, 1H), 4.64 (d, J = 3.6 Hz, 1H), 4.54~4.49 (m, 1H),1.52 (s, 3H), 
1.29 (t, 6H); 
13C NMR (100 MHz, CDCl3) δ: 165.3, 133.3, 129.7, 129.4, 129.4, 128.5, 128.5, 111.6, 
104.6, 83.9, 78.0, 76.9, 75.2, 26.6, 26.1, 13.3; MS (ESI) m/z 279.2 [M + H]
+. 
3.6. Synthesis of 5-Deoxy-3-O-benzoyl-1,2-O-diacetate-D-xylofuranose 3 
5-Deoxy-3-O-benzoyl-1,2-O-isopropylidene-α-D-xylofuranose 9 (7.15 g, 25.7 mmol) was dissolved 
in AcOH (130 mL) and Ac2O (150 mL). Concentrated H2SO4 (7.5 mL) was added dropwise. The 
solution was stirred at room temperature for 26 h. The solution was poured into H2O (500 mL) and 
extracted with DCM (3 × 100 mL). The combined organic layer was washed with H2O (3 × 50 mL), 
sat. NaHCO3 (3 × 50 mL) and brine (50 mL), then dried with anhydrous Na2SO4. After filtration, the 
resulting solution was evaporated under reduced pressure to afford 10 (6.5 g, 78%) as anomers. It was 
used directly without further purification.  
3.7. Vorbrüggen Glycosylation of 5′-Deoxy-1,2,3-tri-O-acetyl-β-D-xylofuranose 5 and 5-Iodo-7H-
pyrrolo[2,3-d]pyrimidine 10 
To a suspension of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 4 (23.9 g, 85.5 mmoL) in dry 
MeCN (350 mL) was added BSA (20.9 g, 25 mL, 103 mmol) and stirred for 10 min at room temperature. 
After addition of 5-deoxy-3-O-benzoyl-1,2-O-diacetate-D-xylofuranose  3 (27.5 g, 85.5 mmol), 
TMSOTf (19.0 g, 15.5 mL, 85.5 mmol) was added to the mixture. The mixture was stirred for 15 min 
before heating to 80 °C for 12 h. The reaction was cooled to room temperature. Water (400 mL) was 
added to quench the reaction. The solution was extracted with EtOAc (300 mL × 3). The combined 
organic layer was washed with sat. NaHCO3 (350 mL × 1) and brine (350 mL × 2), and dried with 
anhydrous Na2SO4, filtered and evaporated under reduced pressure. The residue was purified over a 
silica gel column (CH2Cl2–EtOAc, 25:1) to afford 10 (26 g, 56%). mp 136–137 °C;
1H NMR 
(400 MHz, DMSO): δ 8.61 (s, 1H), 8.01 (d, 2H, J = 8.4 Hz), 7.79 (s, 1H), 7.63 (t, 1H, J = 6.8 Hz), 7.55 
(d, 2H, J = 7.6 Hz), 6.44 (s, 1H), 5.56 (s, 1H), 5.47 (s, 1H), 4.63 (m, 1H), 2.19 (s, 3H), 1.43 (d, 3H,  
J = 6.4 Hz). 
13C NMR (100 MHz, DMSO): δ 169.1, 165.0, 152.8, 151.2, 150.5, 133.9, 133.4, 132.0, 
129.8, 129.0, 128.5, 117.4, 87.8, 81.3, 78.4, 76.8, 76.6, 52.8, 20.6, 14.6; MS (ESI) m/z 542.2 [M + H]
+; 
HRMS (ESI) m/z calcd for [M + H]
+ C20H18IClN3O5: 541.9974, found: 541.9968. Mar. Drugs 2012, 10 887 
 
3.8. Synthesis of 4-Amino-7-(5′-deoxy-β-D-xylofuranosyl)-5-iodo-pyrrolo[2,3-d]pyrimidine 1 
A solution of 10 (18.2 g, 33.6 mmol) in methanolic ammonia (saturated with NH3 at 0 °C for 2 h, 
200 mL) was placed in an autoclave and stirred at 130 °C for 12 h. After cooling, the mixture was 
concentrated to dryness and the residue was purified over a silica gel column (CH2Cl2–CH3OH, 20:1) 
to afford 1 (10.3 g, 82%) as yellow powder. mp 190-191 °C; [α]25
D −68 (c 0.1, CH3OH); CD: λext 240 nm 
(∆ε −2.6) and λext 209 nm (∆ε −4.4);
1H NMR (400 Hz, DMSO): δ 8.11 (s, 1H, H-2), 7.60 (s, 1H, H-6), 
6.73 (brs, 2H, NH2), 5.96 (d, 1H, J = 1.8 Hz, H-1′), 5.82 (d, 1H, J = 3.6 Hz, OH-2′), 5.69 (d, 1H,  
J = 4.3 Hz, OH-3′), 4.21 (m, 1H, H-4′), 4.12 (dd, 1H, J = 1.8, 3.6 Hz, H-2′), 3.81(dd, 1H, J = 3.6,  
4.3 Hz, H-3′), 1.21 (d, 3H, J = 6.6 Hz, H-5′); 
13C NMR (100 Hz, DMSO): δ 157.6 (C-4), 152.3 (C-2), 
150.0 (C-8), 128.6 (C-6), 103.4 (C-9), 89.8 (C-1′), 82.4 (C-2′), 78.4 (C-4′), 77.0 (C-3′), 51.8 (C-5), 
14.4 (C-5′); HRMS (ESI) m/z calcd for [M + H]
+ C11H14IN4O3: 377.0105, found: 377.0098. 
4. Conclusions  
In conclusion, a practical and efficient approach for 10 g scale synthesis of marine nucleoside  
4-amino-7-(5′-deoxy-β-D-xylofuranosyl)-5-iodo-pyrrolo[2,3-d]pyrimidine  1 was developed on the 
basis of Vorbrüggen glycosylation. It has the merits of cost efficiency, mild reaction conditions, and 
easy access to diversity-oriented derivatives. We are currently in the process of applying this approach 
to other 4-amino-7-(5′-deoxy-β-D-xylofuranosyl)-pyrrolo[2,3-d]pyrimidine derivatives and studying 
their biological activities, such as insecticides, which will be reported in due course.  
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